Roche is buying Promedior to obtain its entire medical portfolio. Promedior’s leading drug candidate is designed to treat idiopathic pulmonary fibrosis, a disease for which only two drugs are approved to treat, one of which is made by Roche.
Under the deal, Roche will pay Promedior another $1 billion if its drug development program meets goals for approval and marketing, according to The Boston Globe.
Bristol-Myers Squibb had a similar deal with Promedior in 2015, but decided last year not to buy the company.
Read the full article here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.